CN Patent

CN112955137A — 组合疗法

Assigned to Mirati Therapeutics Inc · Expires 2021-06-11 · 5y expired

What this patent protects

本发明涉及用于治疗KRas G12C癌症的组合疗法。确切地说，本发明涉及治疗有需要的个体的癌症的方法，其包含向所述个体施用治疗有效量的泛ErbB家族抑制剂与式(I)、式I‑A或式I‑B KRAS G12C抑制剂的组合；包含治疗有效量的所述抑制剂的药物组合物、包含所述组合物的试剂盒和其使用方法。

USPTO Abstract

本发明涉及用于治疗KRas G12C癌症的组合疗法。确切地说，本发明涉及治疗有需要的个体的癌症的方法，其包含向所述个体施用治疗有效量的泛ErbB家族抑制剂与式(I)、式I‑A或式I‑B KRAS G12C抑制剂的组合；包含治疗有效量的所述抑制剂的药物组合物、包含所述组合物的试剂盒和其使用方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN112955137A
Jurisdiction
CN
Classification
—
Expires
2021-06-11
Drug substance claim
No
Drug product claim
No
Assignee
Mirati Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.